Related Experiment Video

Updated: Jun 17, 2026

Assays for Validating Histone Acetyltransferase Inhibitors
09:11

Assays for Validating Histone Acetyltransferase Inhibitors

Published on: August 6, 2020

Histone deacetylase inhibitor therapy in epithelial ovarian cancer

Noriyuki Takai1, Hisashi Narahara

  • 1Department of Obstetrics and Gynecology, Faculty of Medicine, Oita University, Oita 879-5593, Japan.

Journal of Oncology
|January 7, 2010
PubMed

Insights

Histone deacetylase inhibitors (HDACIs) show promise in treating ovarian cancer by inhibiting tumor growth and promoting apoptosis. Clinical trials indicate these epigenetic drugs offer a novel therapeutic strategy with manageable side effects.

Area of Science:

  • Oncology
  • Epigenetics
  • Pharmacology

Background:

  • Epigenetic alterations, including histone deacetylase (HDAC) activity, are implicated in ovarian cancer development through tumor suppressor gene repression.
  • Histone deacetylase inhibitors (HDACIs) represent a potential therapeutic strategy targeting these epigenetic modifications in ovarian cancer.

Purpose of the Study:

  • To review the biological and therapeutic effects of HDAC inhibitors (HDACIs) in the context of ovarian cancer treatment.
  • To focus on preclinical studies and clinical trials evaluating HDACIs for ovarian cancer.

Main Methods:

  • Review of preclinical data from ovarian cancer cell lines and xenograft models assessing HDACI effects.
  • Analysis of clinical trial data investigating the efficacy and safety of HDACI drugs in ovarian cancer patients.

Main Results:

  • HDACIs demonstrated inhibition of cell growth, cell cycle arrest, and apoptosis in various ovarian cancer cell lines.
  • HDACIs induced histone acetylation at the p21(WAF1) gene promoter in human ovarian carcinoma cells.
  • Preclinical studies showed antitumor activity of HDACIs in xenograft models with a favorable side effect profile.

Conclusions:

  • HDAC inhibitors exhibit significant preclinical efficacy and a promising safety profile for ovarian cancer.
  • Clinical trials support HDACI drugs as a novel class of mechanism-based therapeutics for ovarian cancer.

More Related Videos

Simultaneous Measurement of HDAC1 and HDAC6 Activity in HeLa Cells Using UHPLC-MS09:20

Simultaneous Measurement of HDAC1 and HDAC6 Activity in HeLa Cells Using UHPLC-MS

Published on: August 10, 2017

Murine Model for Non-invasive Imaging to Detect and Monitor Ovarian Cancer Recurrence08:55

Murine Model for Non-invasive Imaging to Detect and Monitor Ovarian Cancer Recurrence

Published on: November 2, 2014

Related Concept Videos

Inhibition of Cdk Activity02:34

Inhibition of Cdk Activity

The orderly progression of the cell cycle depends on the activation of Cdk protein by binding to its cyclin partner. However, the cell cycle must be restricted when undergoing abnormal changes. Most cancers correlate to the deregulated cell cycle, and since Cdks are a central component of the cell cycle, Cdk inhibitors are extensively studied to develop anticancer agents. For instance, cyclin D associates with several Cdks, such as Cdk 4/6, to form an active complex. The cyclin D-Cdk4/6 complex...
Inhibition of CDK Activity02:34

Inhibition of CDK Activity

The orderly progression of the cell cycle depends on the activation of Cdk protein by binding to its cyclin partner. However, the cell cycle must be restricted when undergoing abnormal changes. Most cancers correlate to the deregulated cell cycle, and since Cdks are a central component of the cell cycle, Cdk inhibitors are extensively studied to develop anticancer agents. For instance, cyclin D associates with several Cdks, such as Cdk 4/6, to form an active complex. The cyclin D-Cdk4/6 complex...
Treatment Resistant Cancers02:56

Treatment Resistant Cancers

Cancer is the second leading cause of death in the United States. A cancer cell is genetically unstable and hence can mutate faster. They can also modify their microenvironment and escape immune surveillance. The difficulties in treating cancer are further compounded by the emergence of rapid resistance to anticancer drugs. The most common ways to attain resistance in cancer cells include alteration in drug transport and metabolism, modification of drug target, elevated DNA damage response, or...
Cancer Therapies02:49

Cancer Therapies

Cancer therapies are various modes of treatment, such as surgery, radiation therapy, and chemotherapy that are administered to cancer patients.
However, cancer treatments can pose several challenges, as therapies used to kill cancer cells are generally also toxic to normal cells. Moreover, cancer cells mutate rapidly and can develop resistance to chemical agents or radiation therapy. Besides, all types of cancer cells may not respond to the same therapy. Some cancer cells respond to one...
Cancer Therapies02:49

Cancer Therapies

Cancer therapies are various modes of treatment, such as surgery, radiation therapy, and chemotherapy that are administered to cancer patients.
However, cancer treatments can pose several challenges, as therapies used to kill cancer cells are generally also toxic to normal cells. Moreover, cancer cells mutate rapidly and can develop resistance to chemical agents or radiation therapy. Besides, all types of cancer cells may not respond to the same therapy. Some cancer cells respond to one...
Treatment Resistent Cancers02:56

Treatment Resistent Cancers

Cancer is the second leading cause of death in the United States. A cancer cell is genetically unstable and hence can mutate faster. They can also modify their microenvironment and escape immune surveillance. The difficulties in treating cancer are further compounded by the emergence of rapid resistance to anticancer drugs. The most common ways to attain resistance in cancer cells include alteration in drug transport and metabolism, modification of drug target, elevated DNA damage response, or...